Floatz logo

Carboplatin

RAD51B, RAD51C, RAD51D, or RAD54L Mutations

VA Office of Research and DevelopmentSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the RAD51B, RAD51C, RAD51D, or RAD54L Mutations cohort.

Asset / SponsorPhaseRating
Olaparib
VA Office of Research and Development
Phase 2CCC

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →